ComGenex Changes its Name to AMRI Hungary

ComGenex, Inc. has changed its name to AMRI Hungary. The name change results from the acquisition of ComGenex by U.S.-based Albany Molecular Research, Inc.

Located in Budapest, AMRI Hungary has become the European center for AMRI, a global pharmaceutical research, development and manufacturing company with a full range of integrated services-from the identification of hit compounds, to medicinal chemistry SAR optimization, to the production of pharmaceutical ingredients for clinical and commercial use.

Through the acquisition, clients of AMRI Hungary now have access to the comprehensive services provided by AMRI.

Moreover, the integration of AMRI’s research sites in the United States, Europe, and Asia provides the company’s customers with a flexible range of services, capabilities and cost structures.

As part of the AMRI brand, AMRI Hungary integrates early stage drug discovery technologies, including proprietary methods in the area of library synthesis, compound collections and lead discovery.

In the future, AMRI Hungary plans to expand its capabilities in medicinal chemistry and SAR development.

The first advantage of AMRI Hungary’s addition to the global AMRI network is the availability of AMRI Hungary’s expanded and integrated lead-seeking library-which is diverse than before and includes core structures.